ADI-PEG20 or pegargiminase is being hailed as the first drug of its kind to be incorporated successfully with chemotherapy in 20 years. Researchers say…
The U.S. Food and Drug Administration granted fast-track designation to a new therapeutic cancer vaccine. The approval is for UV1 in combination with the…
Scientists in Australia are developing early detection tests for mesothelioma. The Asbestos and Dust Diseases Research Institute’s new test could potentially save lives. According…
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on…
Multinational biopharmaceutical company Polaris Group announced their application for a rolling submission of a new mesothelioma treatment this month. The Biologic License Application…
Results of a new phase 3 clinical trial published in the Journal of Clinical Oncology indicate that a chemoimmunotherapy regimen combining chemotherapy with immunotherapy…
Asbestos is widely known as an occupational hazard, but emerging evidence suggests that prolonged exposure to environmental asbestos could lead to severe autoimmune…
A novel therapy for mesothelioma has been given orphan drug designation by the U.S. Food and Drug Administration. Avenge Bio, a biotechnology company working…
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
Reviewed & Fact-Checked
This page was reviewed by:
Fact-checked and verified content:
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Please read our editorial guidelines to learn more about our content creation and review process.
